Orphan designation: resecabtagene autoleucel Treatment of idiopathic inflammatory myopathy, 18/07/2025 Positive | European Federation of Internal Medicine

Submitted by Anonymous (not verified) on 4 September 2025 - 9:21

Orphan designation: resecabtagene autoleucel Treatment of idiopathic inflammatory myopathy, 18/07/2025 Positive

Link:

https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3094

Source:

Newsletters

Stay informed on our latest news!

Latest Newsletters